Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KSP-910638G is a synthetic heptapeptide imaging agent labeled with the near-infrared dye IRDye800CW. It specifically targets human epithelial growth factor receptor type 2 (HER2; also known as ErbB2), a receptor overexpressed in certain cancers. The compound is designed for molecular imaging applications, particularly for the early detection of gastrointestinal malignancies and potentially other HER2-positive tumors. Developed by the University of Michigan College of Engineering, it has been evaluated in Phase 1 clinical trials to assess its safety when administered orally or topically for fluorescence-guided surgery and diagnostic purposes[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KSP-910638G.